Othmane Mejjad
Research Subjects
Research Interests
Othmane Mejjad has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
X Le Loët
9 shared publications- Olivier Vittecoq
Department of Rheumatology & CIC-CRB 1404, Univ Rouen Normandie, Normandie Univ, CHU Rouen, CHU de Rouen, 1 rue de Germont, 76031 Rouen cedex, Rouen, F-76000, France
7 shared publications - Alain Daragon
CHU de Rouen, Hôpitaux de Rouen, Service de Rhumatologie, Rouen, F-76000, France
6 shared publications P Deshayes
5 shared publicationsX Le Loet
5 shared publicationsL Lucet
4 shared publications
Latest Publications
- 1 September 2009
- Published by Wiley in European journal of pain
- Vol. 13 (S1)
727 WEAK OPIOIDS PROVIDE THE BEST PAIN IMPROVEMENT, DISEASE ACTIVITY AND RELATED DISABILITY IN RHEUMATOID ARTHRITIS AND SPONDYLARTHROPATHY PATIENTS
- 1 September 2009
- Published by Wiley in European journal of pain
- Vol. 13 (S1)
727 WEAK OPIOIDS PROVIDE THE BEST PAIN IMPROVEMENT, DISEASE ACTIVITY AND RELATED DISABILITY IN RHEUMATOID ARTHRITIS AND SPONDYLARTHROPATHY PATIENTS
- 30 November 2006
- Published by Elsevier in Douleurs : Évaluation - Diagnostic - Traitement
- Vol. 7, 119-120
EP03 - Mise en place d’une consultation d’électrostimulation transcutanée (TENS) au centre de la douleur du CHU De Rouen
- 30 November 2006
- Published by Elsevier in Douleurs : Évaluation - Diagnostic - Traitement
- Vol. 7, 119-120
EP03 - Mise en place d’une consultation d’électrostimulation transcutanée (TENS) au centre de la douleur du CHU De Rouen
- 1 September 2006
- Published by Wiley in European journal of pain
- Vol. 10 (S1) , S209b-S209
805 IS ANALGESIC USE CORRELATED TO PAIN, DISEASE ACTIVITY OR DISABILITY LEVELS DURING RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS?
- 1 September 2006
- Published by Wiley in European journal of pain
- Vol. 10 (S1) , S209b-S209
805 IS ANALGESIC USE CORRELATED TO PAIN, DISEASE ACTIVITY OR DISABILITY LEVELS DURING RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS?
- Open Access
- 3 July 2006
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (4) , R105
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
As indicators of responsiveness to a tumour necrosis factor (TNF)α blocking agent (infliximab) are lacking in rheumatoid arthritis, we have used gene profiling in peripheral blood mononuclear cells to predict a good versus poor response to infliximab. Thirty three patients with very active disease (Disease Activity Score 28 >5.1) that resisted weekly methotrexate therapy were given infliximab at baseline, weeks 2 and 6, and every 8th week thereafter. The patients were categorized as responders if a change of Disease Activity Score 28 = 1.2 was obtained at 3 months. Mononuclear cell RNAs were collected at baseline and at three months from responders and non-responders. The baseline RNAs were hybridised to a microarray of 10,000 non-redundant human cDNAs. In 6 responders and 7 non-responders, 41 mRNAs identified by microarray analysis were expressed as a function of the response to treatment and an unsupervised hierarchical clustering perfectly separated these responders from non-responders. The informativeness of 20 of these 41 transcripts, as measured by qRT-PCR, was re-assessed in 20 other patients. The combined levels of these 20 transcripts properly classified 16 out of 20 patients in a leave-one-out procedure, with a sensitivity of 90% and a specificity of 70%, whereas a set of only 8 transcripts properly classified 18/20 patients. Trends for changes in various transcript levels at three months tightly correlated with treatment responsiveness and a down-regulation of specific transcript levels was observed in non-responders only. Our gene profiling obtained by a non-invasive procedure should now be used to predict the likely responders to an infliximab/methotrexate combination.
- 3 July 2006
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 8 (4) , R105
Open AccessGene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
As indicators of responsiveness to a tumour necrosis factor (TNF)α blocking agent (infliximab) are lacking in rheumatoid arthritis, we have used gene profiling in peripheral blood mononuclear cells to predict a good versus poor response to infliximab. Thirty three patients with very active disease (Disease Activity Score 28 >5.1) that resisted weekly methotrexate therapy were given infliximab at baseline, weeks 2 and 6, and every 8th week thereafter. The patients were categorized as responders if a change of Disease Activity Score 28 = 1.2 was obtained at 3 months. Mononuclear cell RNAs were collected at baseline and at three months from responders and non-responders. The baseline RNAs were hybridised to a microarray of 10,000 non-redundant human cDNAs. In 6 responders and 7 non-responders, 41 mRNAs identified by microarray analysis were expressed as a function of the response to treatment and an unsupervised hierarchical clustering perfectly separated these responders from non-responders. The informativeness of 20 of these 41 transcripts, as measured by qRT-PCR, was re-assessed in 20 other patients. The combined levels of these 20 transcripts properly classified 16 out of 20 patients in a leave-one-out procedure, with a sensitivity of 90% and a specificity of 70%, whereas a set of only 8 transcripts properly classified 18/20 patients. Trends for changes in various transcript levels at three months tightly correlated with treatment responsiveness and a down-regulation of specific transcript levels was observed in non-responders only. Our gene profiling obtained by a non-invasive procedure should now be used to predict the likely responders to an infliximab/methotrexate combination.
- 1 November 2004
- Published by Elsevier in Joint Bone Spine
- Vol. 71 (6) , 542-545
Foot orthotics decrease pain but do not improve gait in rheumatoid arthritis patients
- 1 November 2004
- Published by Elsevier in Joint Bone Spine
- Vol. 71 (6) , 542-545
Foot orthotics decrease pain but do not improve gait in rheumatoid arthritis patients
- 28 February 2001
- Published by Elsevier in Joint Bone Spine
- Vol. 68 (1) , 76-78
A shock associated with adult-onset Still’s disease
- 28 February 2001
- Published by Elsevier in Joint Bone Spine
- Vol. 68 (1) , 76-78
A shock associated with adult-onset Still’s disease
- 16 December 2000
- Vol. 29 (39) , 2157-61
[Treatment of arthroses in the elderly patient].
Elderly subjects with osteoarthritis are treated with analgesic drugs, non-steroidal antiinflammatory drugs (NSAID) and intra-articular corticosteroid injections as well as symptomatic slow acting drugs in osteoarthritis (Sy-SADOA). Initial treatment for osteoarthritis pain should be paracetamol, followed by NSAID if necessary, especially in the elderly, because of their adverse effects. Sy-SADOA are effective on pain and function with a persistent effect, allowing the reduction of analgesic and NSAID dosage.
- 16 December 2000
- Vol. 29 (39) , 2157-61
[Treatment of arthroses in the elderly patient].
Elderly subjects with osteoarthritis are treated with analgesic drugs, non-steroidal antiinflammatory drugs (NSAID) and intra-articular corticosteroid injections as well as symptomatic slow acting drugs in osteoarthritis (Sy-SADOA). Initial treatment for osteoarthritis pain should be paracetamol, followed by NSAID if necessary, especially in the elderly, because of their adverse effects. Sy-SADOA are effective on pain and function with a persistent effect, allowing the reduction of analgesic and NSAID dosage.
- 1 May 2000
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 8 (3) , 230-235
Efficacy of etodolac on gait in hip osteoarthritis as assessed by Bessou's locometer: a randomized, crossover, double-blind study versus placebo
- 1 May 2000
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 8 (3) , 230-235
Efficacy of etodolac on gait in hip osteoarthritis as assessed by Bessou's locometer: a randomized, crossover, double-blind study versus placebo
- 1 December 1997
- Vol. 64 (12) , 835-8
Leiomyosarcoma of the tibia. Report of a case.
A 48-year-old man with an unremarkable medical history was admitted for a painful swelling over the anteromedial aspect of his right leg. Radiographs disclosed heterogeneity of the proximal tibia, with increased uptake on the bone scan. Computed tomography findings consisted of heterogeneity of the proximal tibial metaphysis and diaphysis with subtle cortical osteolysis, periosteal appositions and soft tissue involvement. Magnetic resonance images showed low signal from the metaphysis, diaphysis and soft tissues on T1 sections that enhanced after gadolinium and converted to high signal on T2 images. Lung metastases were also found. Histologic features were consistent with leiomyosarcoma, which was considered to have originated in the tibia since no other primary localization was found. Combination chemotherapy was successful in eliminating the clinical manifestations and clearing the lung metastases. Six months later, the same chemotherapy regimen failed to improve a local and pulmonary recurrence and the patient died a few months later. Primary leiomyosarcoma of bone is a rare tumor, of which one of the most characteristic locations is the proximal third of the tibia. Magnetic resonance imaging with both T1- and T2-weighted sequences is essential to evaluate intramedullary and soft tissue tumor spread. To our knowledge, there are no characteristic signal patterns allowing to differentiate leiomyosarcoma from other primary malignancies of bone. Immunohistochemical and electron microscope studies are useful diagnostic tools.
- 1 December 1997
- Vol. 64 (12) , 835-8
Leiomyosarcoma of the tibia. Report of a case.
A 48-year-old man with an unremarkable medical history was admitted for a painful swelling over the anteromedial aspect of his right leg. Radiographs disclosed heterogeneity of the proximal tibia, with increased uptake on the bone scan. Computed tomography findings consisted of heterogeneity of the proximal tibial metaphysis and diaphysis with subtle cortical osteolysis, periosteal appositions and soft tissue involvement. Magnetic resonance images showed low signal from the metaphysis, diaphysis and soft tissues on T1 sections that enhanced after gadolinium and converted to high signal on T2 images. Lung metastases were also found. Histologic features were consistent with leiomyosarcoma, which was considered to have originated in the tibia since no other primary localization was found. Combination chemotherapy was successful in eliminating the clinical manifestations and clearing the lung metastases. Six months later, the same chemotherapy regimen failed to improve a local and pulmonary recurrence and the patient died a few months later. Primary leiomyosarcoma of bone is a rare tumor, of which one of the most characteristic locations is the proximal third of the tibia. Magnetic resonance imaging with both T1- and T2-weighted sequences is essential to evaluate intramedullary and soft tissue tumor spread. To our knowledge, there are no characteristic signal patterns allowing to differentiate leiomyosarcoma from other primary malignancies of bone. Immunohistochemical and electron microscope studies are useful diagnostic tools.